title: Bortezomib and panobinostat combination is effective against PTCL.
authors.forename: Colin
authors.initials: C
authors.lastname: Phipps
authors.forename: Swee Jin
authors.initials: SJ
authors.lastname: Mok
authors.forename: Ai Leen
authors.initials: AL
authors.lastname: Ang
authors.forename: Yeow Tee
authors.initials: YT
authors.lastname: Goh
authors.forename: Daryl
authors.initials: D
authors.lastname: Tan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage*; D007211:Indoles; D016411:Lymphoma, T-Cell, Peripheral / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D000077767:Panobinostat; D049268:Positron-Emission Tomography; D011719:Pyrazines / Q000008:administration & dosage*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D006877:Hydroxamic Acids; D007211:Indoles; D011719:Pyrazines; D000069286:Bortezomib; D000077767:Panobinostat